Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elijah Weber

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Bioethics|August 27, 2015
Moral Distress, Workplace Health, and Intrinsic HarmElijah Weber
Narrative Inquiry in Bioethics|July 18, 2017
Reframing Medical Appropriateness: A Case Study Concerning the Use of Life-Sustaining Technologies for a Patient With Profoundly Diminished Quality of LifeColleen M Gallagher, Elijah Weber, Nisha Rathi
The Hastings Center Report|April 11, 2021
In This Together: Navigating Ethical Challenges Posed by Family Clustering during the Covid-19 PandemicNicole R Van Buren, Elijah Weber, Mark J Bliton, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2024
Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairmentVamshi Jogiraju, Elijah Weber, Jason Hindman, et al.
Journal of Clinical Pharmacology|January 26, 2023
Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor AgonistElijah Weber, Islam R Younis, Cara Nelson, et al.
Clinical Pharmacokinetics|March 11, 2023
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) AgonistIslam Younis, Elijah Weber, Cara Nelson, et al.
Clinical Pharmacokinetics|January 18, 2024
Pharmacokinetics, Disposition, and Biotransformation of [<sup>14</sup>C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous InfusionElijah Weber, Raju Subramanian, William Rowe, et al.
Journal of the American Society of Nephrology : JASN|August 12, 2015
A Quantitative Approach to Screen for Nephrotoxic Compounds In VitroMelanie Adler, Susanne Ramm, Marc Hafner, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Bioethics|August 27, 2015
Moral Distress, Workplace Health, and Intrinsic HarmElijah Weber
Narrative Inquiry in Bioethics|July 18, 2017
Reframing Medical Appropriateness: A Case Study Concerning the Use of Life-Sustaining Technologies for a Patient With Profoundly Diminished Quality of LifeColleen M Gallagher, Elijah Weber, Nisha Rathi
The Hastings Center Report|April 11, 2021
In This Together: Navigating Ethical Challenges Posed by Family Clustering during the Covid-19 PandemicNicole R Van Buren, Elijah Weber, Mark J Bliton, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2024
Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairmentVamshi Jogiraju, Elijah Weber, Jason Hindman, et al.
Journal of Clinical Pharmacology|January 26, 2023
Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor AgonistElijah Weber, Islam R Younis, Cara Nelson, et al.
Clinical Pharmacokinetics|March 11, 2023
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) AgonistIslam Younis, Elijah Weber, Cara Nelson, et al.
Clinical Pharmacokinetics|January 18, 2024
Pharmacokinetics, Disposition, and Biotransformation of [<sup>14</sup>C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous InfusionElijah Weber, Raju Subramanian, William Rowe, et al.
Journal of the American Society of Nephrology : JASN|August 12, 2015
A Quantitative Approach to Screen for Nephrotoxic Compounds In VitroMelanie Adler, Susanne Ramm, Marc Hafner, et al.
Pageof 1